Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Antibody Mediated Rejection and T-cell Mediated Rejection Molecular Signatures Using Next-Generation Sequencing in Kidney Transplant Biopsies

  • Cortes Garcia, Esteban
  • Giarraputo, Alessia
  • Racapé, Maud
  • Goutaudier, Valentin
  • Ursule-Dufait, Cindy
  • de la Grange, Pierre
  • Adoux, Lucie
  • Raynaud, Marc
  • Couderau, Clément
  • Mezine, Fariza
  • Dagobert, Jessie
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
  • Moreso, Francesc|||0000-0002-7267-3963
  • Villard, Jean
  • Halleck, Fabian
  • Giral, Magali|||0000-0001-7641-1592
  • Brouard, Sophie
  • Danger, Richard
  • Gourraud, Pierre-Antoine|||0000-0003-1131-9554
  • Rabant, Marion|||0000-0001-5696-6478
  • Couzi, Lionel
  • Le Quintrec, Moglie
  • Kamar, Nassim
  • Morelon, Emmanuel
  • Vrtovsnik, François
  • Taupin, Jean-Luc
  • Snanoudj, Renaud
  • Legendre, Christophe
  • Anglicheau, Dany|||0000-0001-5793-6174
  • Budde, K.
  • Lefaucheur, Carmen
  • Loupy, Alexandre|||0000-0003-3388-7747
  • Aubert, Olivier
Recently, interest in transcriptomic assessment of kidney biopsies has been growing. This study investigates the use of NGS to identify gene expression changes and analyse the pathways involved in rejection. An Illumina bulk RNA sequencing on the polyadenylated RNA of 770 kidney biopsies was conducted. Differentially-expressed genes (DEGs) were determined for AMR and TCMR using DESeq2. Genes were segregated according to their previous descriptions in known panels (microarray or the Banff Human Organ Transplant (B-HOT) panel) to obtain NGS-specific genes. Pathway enrichment analysis was performed using the Reactome and Kyoto Encyclopaedia of Genes and Genomes (KEGG) public repositories. The differential gene expression using NGS analysis identified 6,141 and 8,478 transcripts associated with AMR and TCMR. While most of the genes identified were included in the microarray and the B-HOT panels, NGS analysis identified 603 (9.8%) and 1,186 (14%) new specific genes. Pathways analysis showed that the B-HOT panel was associated with the main immunological processes involved during AMR and TCMR. The microarrays specifically integrated metabolic functions and cell cycle progression processes. Novel NGS-specific based transcripts associated with AMR and TCMR were discovered, which might represent a novel source of targets for drug designing and repurposing.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation

  • Kervella, Delphine|||0000-0001-8069-6105
  • Casanova Ferrer, Franc
  • Kotton, Camille N
  • Donadeu, Laura|||0000-0002-5089-5047
  • Kumar, Deepali|||0000-0003-1961-0477
  • Pineda, Silvia|||0000-0003-4017-1480
  • Crespo, Elena
  • Meneghini, Maria|||0000-0001-7307-923X
  • González-Costelo, José
  • García Romero, Elena|||0000-0003-4090-6571
  • Lladó, Laura|||0000-0002-3717-3306
  • Cachero, Alba|||0000-0002-0010-4534
  • Melilli, Edoardo|||0000-0001-6965-3745
  • Torres, Irina B.|||0000-0003-3304-0810
  • Martínez Lacalle, Anna
  • Castañeda, Zaira|||0000-0001-7526-1078
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Len, Oscar|||0000-0002-1819-3141
  • Los-Arcos, Ibai|||0000-0001-8835-2702
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Giral, Magali|||0000-0001-7641-1592
  • Brouard, Sophie
  • Girardin, François R.
  • Villard, Jean
  • Budde, K.
  • Lefaucheur, Carmen
  • Loupy, Alexandre|||0000-0003-3388-7747
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard, Oriol|||0000-0001-9468-7920
The interferon gamma (IFN-γ) enzyme-linked immunosorbent spot is a highly sensitive immune assay that enables the assessment of cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) and can identify at-risk transplant patients of CMV infection; however, its clinical implementation remains elusive. We developed a novel CMV-CMI risk-score based on the standardized T-SPOT.CMV assay against 2 CMV antigens (immediate-early protein 1 [IE-1] and 65 kDa phosphoprotein [pp65]), a biomarker predicting CMV infection, both high viral replication, and disease by performing a pooled analysis of 570 kidney transplants participating in different clinical trials and subsequently validating it in 146 consecutives solid organ transplants (SOT) in an interventional trial. By incorporating clinical variables into the CMV-CMI risk-score, we built an integrative prognostic system quantifying the risk of CMV infection (CMV-PrognosTIC score) using elastic net penalized regression analysis. In the pooled derivation cohort, whereas specific IE-1/pp65-specific CMV-CMI frequencies independently correlated with high risk of CMV infection (areas under the curve [AUCs]: 0.694, P < 0.0001; 0.719, P < 0.0001, respectively), by combining both responses, 3 CMV-CMI risk-scores appeared, accurately discriminating low-risk (LR) from intermediate-risk (IR) and high-risk (HR) patients (98.7% negative predictive value [NPV], 97.2% sensitivity). Its prospective implementation guiding decision-making in an independent SOT cohort confirmed the very high NPV and sensitivity identifying LR patients. By integrating type of preventive therapy, patient age, and donor (D) and recipient (R) CMV-serostatus to the CMV-CMI risk-score, we generated a global risk-prognostic model showing accurate discrimination and calibration in both derivation (AUC: 0.807) and validation cohorts (AUC: 0.719). Conclusion: We developed a robust CMV-PrognosTIC score to quantify the risk of CMV infection in SOT, which may be readily implemented in clinical transplantation to personalize CMV preventive therapies.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept

  • Pernin, Vincent
  • Meneghini, Maria
  • Torija Recasens, Alba
  • Jouve, Thomas
  • Del Bello, Arnaud
  • Sanz Muñoz, Iván
  • Eiros, Jose Maria
  • Donadeu, Laura
  • Polo, Carol
  • Morandeira, Francisco
  • Navarro, Sergio
  • Masuet Aumatell, Cristina
  • Favà Buch, Alexandre
  • Lequintrec, Moglie
  • Kamar, Nassim
  • Crespo, Elena
  • Bestard Matamoros, Oriol
Emerging data suggest that costimulation blockade with belatacept effectively controls humoral alloimmune responses. However, whether this effect may be deleterious for protective anti-infectious immunity remains poorly understood. We performed a mechanistic exploratory study in 23 kidney transplant recipients receiving either the calcineurin-inhibitor tacrolimus (Tac, n=14) or belatacept (n=9) evaluating different cellular immune responses after influenza vaccination such as activated T follicular Helper (Tfh), plasmablasts and H1N1 hemagglutinin (HA)-specific memory B cells (HA(+)mBC) by flow-cytometry, and anti-influenza antibodies by hemagglutination inhibition test (HI), at baseline and days 10, 30 and 90 post-vaccination. The proportion of CD4+CD54RA-CXCR5+ Tfh was lower in belatacept than Tac patients at baseline (1.86%[1.25-3.03] vs 4.88%[2.40-8.27], p=0.01) and remained stable post-vaccination. At M3, HA(+)mBc were significantly higher in Tac-treated patients (0.56%[0.32-1.49] vs 0.27%[0.13-0.44], p=0.04) and correlated with activated Tfh numbers. When stratifying patients according to baseline HA(+)mBc frequencies, belatacept patients with low HA(+)mBC displayed significantly lower HA(+)mBc increases after vaccination than Tac patients (1.28[0.94-2.4] vs 2.54[1.73-5.70], p=0.04). Also, belatacept patients displayed significantly lower seroprotection rates against H1N1 at baseline than Tac-treated patients (44.4% vs 84.6%) as well as lower seroconversion rates at days 10, 30 and 90 after vaccination (50% vs 0%, 63.6% vs 0%, and 63.6% vs 0%, respectively). We show the efficacy of belatacept inhibiting T-dependent antigen-specific humoral immune responses, active immunization should be highly encouraged before starting belatacept therapy.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Pretransplant Donor-specific IFN gamma ELISPOT as a Predictor of Graft Rejection: A Diagnostic Test Accuracy Meta-analysis

  • Montero, Nuria
  • Farouk, Samira
  • Gandolfini, Ilaria
  • Crespo, Elena
  • Jarque, Marta
  • Meneghini, Maria
  • Torija Recasens, Alba
  • Maggiore, Umberto
  • Cravedi, Paolo
  • Bestard Matamoros, Oriol
Background. Pretransplant interferon-gamma enzyme-linked immunospot (IFN-gamma ELISPOT) has been proposed as a tool to quantify alloreactive memory T cells and estimate the risk of acute rejection (AR) after kidney transplantation, but studies have been inconclusive so far. We performed a meta-analysis to evaluate the association between pretransplant IFN-gamma ELISPOT and AR and assess its predictive accuracy at the individual level. Methods. We estimated the pooled summary of odds ratio for AR and the joined sensitivity and specificity for predicting AR using random-effects and hierarchical summary receiver-operating characteristic models. We used meta-regression models with the Monte Carlo permutation method to adjust for multiple tests to explain sensitivity and specificity heterogeneity across studies. The meta-analytic estimates of sensitivity and specificity were used to calculate positive and negative predictive values across studies. Results. The analysis included 12 studies and 1181 patients. IFN-gamma ELISPOT was significantly associated with increased AR risk (odds ratio: 3.29; 95% confidence interval (CI), 2.34-4.60); hierarchical summary receiver operating characteristic jointly estimated sensitivity and specificity values were 64.9% (95% CI, 53.7%-74.6%) and 65.8% (95% CI, 57.4%-73.5%), respectively, with moderate heterogeneity across studies. After adjusting for multiple testing, meta-regression models showed that thymoglobulin induction, recipient black ethnicity, living versus deceased donors, and geographical location did not affect sensitivity or specificity. Because of the varying AR incidence of the studies, positive and negative predictive values ranged between 16%-60% and 70%-95%, respectively. Conclusions. Pretransplant IFN-gamma ELISPOT is significantly associated with increased risk of AR but provides suboptimal predictive ability at an individual level. Prospective randomized clinical trials are warranted.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept

  • Pernin, Vincent
  • Meneghini, Maria Antonia Emilia
  • Torija Recasens, Alba
  • Del Bello, Arnaud
  • Sanz-Muñoz, Iván
  • Crespo Gimeno, Elena Isabel
  • Bestard Matamoros, Oriol
  • Donadeu Casassas, Laura
  • Jouve, Thomas
Inhibidores de la calcineurina; Vacunación antigripal; Trasplante de riñón, Calcineurin inhibitors; Influenza vaccination; Kidney transplantation, Inhibidors de la calcineurina; Vacunació antigripal; Trasplantament de ronyó, Emerging data suggest that costimulation blockade with belatacept effectively controls humoral alloimmune responses. However, whether this effect may be deleterious for protective anti-infectious immunity remains poorly understood. We performed a mechanistic exploratory study in 23 kidney transplant recipients receiving either the calcineurin-inhibitor tacrolimus (Tac, n=14) or belatacept (n=9) evaluating different cellular immune responses after influenza vaccination such as activated T follicular Helper (Tfh), plasmablasts and H1N1 hemagglutinin (HA)-specific memory B cells (HA+mBC) by flow-cytometry, and anti-influenza antibodies by hemagglutination inhibition test (HI), at baseline and days 10, 30 and 90 post-vaccination. The proportion of CD4+CD54RA-CXCR5+ Tfh was lower in belatacept than Tac patients at baseline (1.86%[1.25-3.03] vs 4.88%[2.40-8.27], p=0.01) and remained stable post-vaccination. At M3, HA+mBc were significantly higher in Tac-treated patients (0.56%[0.32-1.49] vs 0.27%[0.13-0.44], p=0.04) and correlated with activated Tfh numbers. When stratifying patients according to baseline HA+mBc frequencies, belatacept patients with low HA+mBC displayed significantly lower HA+mBc increases after vaccination than Tac patients (1.28[0.94-2.4] vs 2.54[1.73-5.70], p=0.04). Also, belatacept patients displayed significantly lower seroprotection rates against H1N1 at baseline than Tac-treated patients (44.4% vs 84.6%) as well as lower seroconversion rates at days 10, 30 and 90 after vaccination (50% vs 0%, 63.6% vs 0%, and 63.6% vs 0%, respectively). We show the efficacy of belatacept inhibiting T-dependent antigen-specific humoral immune responses, active immunization should be highly encouraged before starting belatacept therapy., This work was supported by the Instituto de Salud Carlos III (ISCIII) (grant numbers ICI14/00242 and PI16/01321, PI19/01710) and by the European Union’s Horizon 2020 Research and innovation program (grant agreement 754995). Also, this work was partly supported by the SLT002/16/00183 grant, from the Department of Health of the Generalitat de Catalunya by the call “Accioí instrumental de programes derecerca orientats en l’àmbit de la recerca i la innovacioí en salut.” The authors thank the Research Centers of Catalonia (CERCA) Programme/Generalitat de Catalunya for institutional support. OB was awarded with an intensification grant from the “Instituto de Salud Carlos III” [INT19/00051].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immunosuppressant drugs and quality-of-life outcomes in kidney transplant recipients: An international cohort study (EU-TRAIN)

  • Girardin, François R
  • Nicolet, Anna
  • Bestard, Oriol
  • lefaucheur, carmen
  • Budde, Klemens
  • Halleck, Fabian
Immunosuppressant; Quality of life; Transplantation, Immunosupressor; Qualitat de vida; Trasplantament, Inmunosupresor; Calidad de vida; Trasplante, Introduction: Patient-Reported Outcomes (PRO) integrate a wide range of holistic dimensions that arenot captured within clinical outcomes. Particularly, from induction treatment to maintenance therapy, patient quality-of-life (QoL) of kidney transplant recipients have been sparsely investigated in international settings. Methods: In a prospective, multi-centric cohort study, including nine transplant centers in four countries, we explored the QoL during the year following transplantation using validated elicitation instruments (EQ-5D-3L index with VAS) in a population of kidney transplant patients receiving immunosuppressive therapies. Calcineurin inhibitors (tacrolimus and ciclosporin), IMPD inhibitor (mycophenolate mofetil), and mTOR inhibitors (everolimus and sirolimus) were the standard-of-care (SOC) medications, together with tapering glucocorticoid therapy. We used EQ-5D and VAS data as QoL measures alongside descriptive statistics at inclusion, per country and hospital center. We computed the proportions of patients with different immunosuppressive therapy patterns, and using bivariate and multivariate analyses, assessed the variations of EQ-5D and VAS between baseline (i.e., inclusion Month 0) and follow up visits (Month 12). Results: Among 542 kidney transplant patients included and followed from November 2018 to June 2021, 491 filled at least one QoL questionnaire at least at baseline (Month 0). The majority of patients in all countries received tacrolimus and mycophenolate mofetil, ranging from 90.0% in Switzerland and Spain to 95.8% in Germany. At M12, a significant proportion of patients switched immunosuppressive drugs, with proportion varying from 20% in Germany to 40% in Spain and Switzerland. At visit M12, patients who kept SOC therapy had higher EQ-5D (by 8 percentage points, p < 0.05) and VAS (by 4 percentage points, p < 0.1) scores than switchers. VAS scores were generally lower than EQ-5D (mean 0.68 [0.5–0.8] vs. 0.85 [0.8–1]). Discussion: Although overall a positive trend in QoL was observed, the formal analyses did not show any significant improvements in EQ-5D scores or VAS. Only when the effect of a therapy use was separated from the effect of switching, the VAS score was significantly worse for switchers during the follow up period, irrespective of the therapy type. If adjusted for patient characteristics and medical history (e.g., gender, BMI, eGRF, history of diabetes), VAS and EQ-5D delivered sound PRO measures for QoL assessments during the year following renal transplantation., The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 754995. Open access funding by University of Lausanne.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

High-dimensional mass cytometry identified circulating natural killer T-cell subsets associated with protection from cytomegalovirus infection in kidney transplant recipients

  • JOUVE, Thomas
  • Bin, Sofia
  • Hartzell, Susan
  • Torija Recasens, Alba
  • Jarque, Marta
  • KERVELLA, Delphine
  • Zuñiga-Vergara, Jose-Miguel
  • Font-Miñarro, Cristina
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Perelló, Manel
  • Donadeu Casassas, Laura
  • Martínez Gallo, Mónica
  • Meneghini, Maria
  • TOAPANTA, NÉSTOR
  • Moreso, Francesc
  • Bestard, Oriol
  • Crespo, Elena
Cytomegalovirus; Kidney transplantation; Mass spectrometry, Citomegalovirus; Trasplante de riñón; Espectrometría de masas, Citomegalovirus; Trasplantament de ronyó; Espectrometria de masses, Cytomegalovirus (CMV) infection is associated with poor kidney transplant outcomes. While innate and adaptive immune cells have been implicated in its prevention, an in-depth characterization of the in vivo kinetics of multiple cell subsets and their role in protecting against CMV infection has not been achieved. Here, we performed high-dimensional immune phenotyping by mass cytometry, and functional assays, on 112 serially collected samples from CMV seropositive kidney transplant recipients. Advanced unsupervised deep learning analysis was used to assess immune cell populations that significantly correlated with prevention against CMV infection and anti-viral immune function. Prior to infection, kidney transplant recipients who developed CMV infection showed significantly lower CMV-specific cell-mediated immune (CMI) frequencies than those that did not. A broad diversity of circulating cell subsets within innate and adaptive immune compartments were associated with CMV infection or protective CMV-specific CMI. While percentages of CMV (tetramer-stained)-specific T cells associated with high CMI responses and clinical protection, circulating CD3+CD8midCD56+ NK-T cells overall strongly associated with low CMI and subsequent infection. However, three NK-T cell subsets sharing the CD11b surface marker associated with CMV protection and correlated with strong anti-viral CMI frequencies in vitro. These data were validated in two external independent cohorts of kidney transplant recipients. Thus, we newly describe the kinetics of a novel NK-T cell subset that may have a protective role in post-transplantation CMV infection. Our findings pave the way to more mechanistic studies aimed at understanding the function of these cells in protection against CMV infection., LD received a research fellowship grant from the “Instituto de Salud Carlos III” (FI22/00252). TJ received a fellowship grant from the European Society of Organ Transplantation (2020 fellowship grant). PC is acting as a consultant for Chinook Therapeutics and has received research funding from Chinook Therapeutics. OB’s research activity is partly supported by Instituto de Salud Carlos III (grant numbers PI19/01710 and PI22/01019; cofunded by the European Regional Development Fund, a way to build Europe) and redes de Investigación Cooperativa Orientadas a Resultados en Salud consortia by the Instituto de Salud Carlos III. Also, the work was partially funded by a European Union Horizon 2020 research and innovation program under grant agreement 754995 (EUTRAIN).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept

  • Pernin, Vincent
  • Meneghini, Maria
  • Torija Recasens, Alba
  • Jouve, Thomas
  • Del Bello, Arnaud
  • Sanz Muñoz, Iván
  • Eiros, Jose Maria
  • Donadeu, Laura
  • Polo, Carol
  • Morandeira, Francisco
  • Navarro, Sergio
  • Masuet Aumatell, Cristina
  • Favà Buch, Alexandre
  • Lequintrec, Moglie
  • Kamar, Nassim
  • Crespo, Elena
  • Bestard Matamoros, Oriol
Emerging data suggest that costimulation blockade with belatacept effectively controls humoral alloimmune responses. However, whether this effect may be deleterious for protective anti-infectious immunity remains poorly understood. We performed a mechanistic exploratory study in 23 kidney transplant recipients receiving either the calcineurin-inhibitor tacrolimus (Tac, n=14) or belatacept (n=9) evaluating different cellular immune responses after influenza vaccination such as activated T follicular Helper (Tfh), plasmablasts and H1N1 hemagglutinin (HA)-specific memory B cells (HA(+)mBC) by flow-cytometry, and anti-influenza antibodies by hemagglutination inhibition test (HI), at baseline and days 10, 30 and 90 post-vaccination. The proportion of CD4+CD54RA-CXCR5+ Tfh was lower in belatacept than Tac patients at baseline (1.86%[1.25-3.03] vs 4.88%[2.40-8.27], p=0.01) and remained stable post-vaccination. At M3, HA(+)mBc were significantly higher in Tac-treated patients (0.56%[0.32-1.49] vs 0.27%[0.13-0.44], p=0.04) and correlated with activated Tfh numbers. When stratifying patients according to baseline HA(+)mBc frequencies, belatacept patients with low HA(+)mBC displayed significantly lower HA(+)mBc increases after vaccination than Tac patients (1.28[0.94-2.4] vs 2.54[1.73-5.70], p=0.04). Also, belatacept patients displayed significantly lower seroprotection rates against H1N1 at baseline than Tac-treated patients (44.4% vs 84.6%) as well as lower seroconversion rates at days 10, 30 and 90 after vaccination (50% vs 0%, 63.6% vs 0%, and 63.6% vs 0%, respectively). We show the efficacy of belatacept inhibiting T-dependent antigen-specific humoral immune responses, active immunization should be highly encouraged before starting belatacept therapy.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Antibody Mediated Rejection and T-cell Mediated Rejection Molecular Signatures Using Next-Generation Sequencing in Kidney Transplant Biopsies

  • Cortes Garcia, Esteban
  • Giarraputo, Alessia
  • Racapé, Maud
  • Goutaudier, Valentin
  • Ursule-Dufait, Cindy
  • de la Grange, Pierre
  • Bestard, Oriol
  • Moreso, Francesc
Kidney biopsies; Kidney transplantation; Next generation sequencing, Biopsias de riñón; Trasplante de riñón; Secuenciación de nueva generación, Biòpsies de ronyó; Trasplantament de ronyó; Seqüenciació de nova generació, Recently, interest in transcriptomic assessment of kidney biopsies has been growing. This study investigates the use of NGS to identify gene expression changes and analyse the pathways involved in rejection. An Illumina bulk RNA sequencing on the polyadenylated RNA of 770 kidney biopsies was conducted. Differentially-expressed genes (DEGs) were determined for AMR and TCMR using DESeq2. Genes were segregated according to their previous descriptions in known panels (microarray or the Banff Human Organ Transplant (B-HOT) panel) to obtain NGS-specific genes. Pathway enrichment analysis was performed using the Reactome and Kyoto Encyclopaedia of Genes and Genomes (KEGG) public repositories. The differential gene expression using NGS analysis identified 6,141 and 8,478 transcripts associated with AMR and TCMR. While most of the genes identified were included in the microarray and the B-HOT panels, NGS analysis identified 603 (9.8%) and 1,186 (14%) new specific genes. Pathways analysis showed that the B-HOT panel was associated with the main immunological processes involved during AMR and TCMR. The microarrays specifically integrated metabolic functions and cell cycle progression processes. Novel NGS-specific based transcripts associated with AMR and TCMR were discovered, which might represent a novel source of targets for drug designing and repurposing., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The EU-TRAIN study was funded by the European Union’s Horizon 2020 research and innovation program under grant agreement no. 754995. The KTD-Innov study was funded by the French government, with financial support managed by the National Research Agency (ANR) under the program “Investissements d’avenir,” with the grant agreement no. ANR-17-RHUS-0010. INSERM-Action thématique incitative sur programme Avenir (ATIP-Avenir) provided financial support.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation

  • Casanova, Franc
  • Kotton, Camille
  • Donadeu Casassas, Laura
  • Kumar, Deepali
  • Pineda SanJuan, Silvia
  • Martínez Lacalle, Anna
  • Castañeda Amado, Zaira Ivette
  • KERVELLA, Delphine
  • Crespo, Elena
  • Meneghini, Maria
  • Torres, Irina B.
  • Martínez Gallo, Mónica
  • Len, Oscar
  • Los-Arcos, Ibai
  • Enrique, Trilla Herrera
  • Miret Alomar, Enric
  • Moreso, Francesc
  • Bestard, Oriol
Breastfeeding; Breast cancer, Lactancia materna; Cáncer de mama, Lactància materna; Càncer de mama, Background: We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants. Methods: This was an international, multicentre, hospital-based, retrospective cohort study including BRCA carriers diagnosed with stage I-III invasive breast cancer at age 40 years or younger between January 2000 and December 2020 (NCT03673306). Locoregional recurrences and/or contralateral breast cancers, disease-free survival (DFS) and overall survival (OS) were compared between patients who breastfed after delivery and those who did not. Results: Among 4732 patients included from 78 centres worldwide, 659 had a pregnancy after breast cancer diagnosis, of whom 474 delivered a child. After excluding patients with uptake of bilateral risk-reducing mastectomy prior to delivery (n = 225) or unknown breastfeeding status (n = 71), 110 (61.8%) breastfed (median duration 5 months) and 68 (38.2%) did not breastfeed. Compared to patients in the no breastfeeding group, those who breastfed were more frequently nulliparous at breast cancer diagnosis (61.8% vs 45.6%) and did not report prior smoking habit (71.8% vs 57.4%).After a median follow up of 7.0 years following delivery, 7-year cumulative incidence of locoregional recurrences and/or contralateral breast cancers was 29% in the breastfeeding group and 37% in the no breastfeeding group (adjusted subdistribution hazard ratio[HR]=1.08, 95%CI 0.57-2.06). No difference in DFS (aHR = 0.83, 95%CI 0.49-1.41) nor in OS (aHR = 1.32, 95%CI 0.31-5.66) was observed. Conclusions: Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers, emphasizing the possibility of achieving a balance between maternal and infant needs without compromising oncological safety., LD received a research fellowship grant from the “Instituto de Salud Carlos III” [FI22/00252]. OB’s research activity is partly supported by Instituto de Salud Carlos III (ISCII) (grant numbers PI19/01710 and PI22/01019) (Cofunded by European Regional Development Fund, ERDF-ESF, a way to build Europe) and RICORS (redes de Investigación Cooperativa Orientadas a Resultados en Salud) consortia by the Instituto de Salud Carlos III. In addition, the work was partially funded by a European Union’s Horizon 2020 research and innovation program under grant agreement No 754995 (EUTRAIN). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding institutions.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Evaluation of non-invasive biomarkers of kidney allograft rejection in a prospective multicenter unselected cohort study (EU-TRAIN)

  • Danger, Richard
  • Catar, Rusan
  • Racapé, Maud
  • Philippe, Aurélie
  • Elias, Michelle
  • Crespo, Elena
  • Goutaudier, Valentin
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Kidney transplantation; Rejection, Biomarcadors; Trasplantament renal; Rebuig, Biomarcadores; Trasplante renal; Rechazo, Non-invasive biomarkers are promising tools for improving kidney allograft rejection monitoring, but their clinical adoption requires more evidence in specifically designed studies. To address this unmet need, we designed the EU-TRAIN study, a large prospective multicentric unselected cohort funded by the European Commission. Here, we included consecutive adult patients who received a kidney allograft in nine European transplant centers between November 2018 and June 2020. We prospectively assessed gene expression levels of 19 blood messenger RNAs, four antibodies targeting non-human leukocyte antigen (HLA) endothelial antigens, together with circulating anti-HLA donor-specific antibodies (DSA). The primary outcome was allograft rejection (antibody-mediated, T cell-mediated, or mixed) in the first year post-transplantation. Overall, 412 patients were included, with 812 biopsies paired with a blood sample. CD4 gene expression was significantly associated with rejection, while circulating anti-HLA DSA had a significant association with allograft rejection and a strong association with antibody-mediated rejection. All other tested biomarkers, including AKR1C3, CD3E, CD40, CD8A, CD9, CTLA4, ENTPD1, FOXP3, GZMB, ID3, IL7R, MS4A1, MZB1, POU2AF1, POU2F1, TCL1A, TLR4, and TRIB1, as well as antibodies against angiotensin II type 1 receptor, endothelin 1 type A receptor, C3a and C5a receptors, did not show significant associations with allograft rejection. The blood messenger RNAs and non-HLA antibodies did not show an additional value beyond standard of care monitoring parameters and circulating anti-HLA DSA to predict allograft rejection in the first year post-transplantation. Thus, our results open avenues for specifically designed studies to demonstrate the clinical relevance and implementation of other candidate non-invasive biomarkers in kidney transplantation practice., The EU-TRAIN study was funded by the European Union’s Horizon 2020 research and innovation program under grant agreement no. 754995. VG received grants from the French-Speaking Society of Transplantation and the French Foundation for Medical Research. RD was supported by the EU-TRAIN study and the ANR project KTD-innov (ANR-17-RHUS-0010) thanks to the French Government financial support managed by the National Research Agency (ANR) within “Investments into the Future” program. OA received a grant from the Foundation Bettencourt-Schueller.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pretransplant Donor-specific IFN gamma ELISPOT as a Predictor of Graft Rejection: A Diagnostic Test Accuracy Meta-analysis

  • Montero, Nuria
  • Farouk, Samira
  • Gandolfini, Ilaria
  • Crespo, Elena
  • Jarque, Marta
  • Meneghini, Maria
  • Torija Recasens, Alba
  • Maggiore, Umberto
  • Cravedi, Paolo
  • Bestard Matamoros, Oriol
Background. Pretransplant interferon-gamma enzyme-linked immunospot (IFN-gamma ELISPOT) has been proposed as a tool to quantify alloreactive memory T cells and estimate the risk of acute rejection (AR) after kidney transplantation, but studies have been inconclusive so far. We performed a meta-analysis to evaluate the association between pretransplant IFN-gamma ELISPOT and AR and assess its predictive accuracy at the individual level. Methods. We estimated the pooled summary of odds ratio for AR and the joined sensitivity and specificity for predicting AR using random-effects and hierarchical summary receiver-operating characteristic models. We used meta-regression models with the Monte Carlo permutation method to adjust for multiple tests to explain sensitivity and specificity heterogeneity across studies. The meta-analytic estimates of sensitivity and specificity were used to calculate positive and negative predictive values across studies. Results. The analysis included 12 studies and 1181 patients. IFN-gamma ELISPOT was significantly associated with increased AR risk (odds ratio: 3.29; 95% confidence interval (CI), 2.34-4.60); hierarchical summary receiver operating characteristic jointly estimated sensitivity and specificity values were 64.9% (95% CI, 53.7%-74.6%) and 65.8% (95% CI, 57.4%-73.5%), respectively, with moderate heterogeneity across studies. After adjusting for multiple testing, meta-regression models showed that thymoglobulin induction, recipient black ethnicity, living versus deceased donors, and geographical location did not affect sensitivity or specificity. Because of the varying AR incidence of the studies, positive and negative predictive values ranged between 16%-60% and 70%-95%, respectively. Conclusions. Pretransplant IFN-gamma ELISPOT is significantly associated with increased risk of AR but provides suboptimal predictive ability at an individual level. Prospective randomized clinical trials are warranted.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation

  • Casanova, Franc
  • Kotton, Camille
  • Donadeu Casassas, Laura
  • Kumar, Deepali
  • Pineda SanJuan, Silvia
  • Martínez Lacalle, Anna
  • Castañeda Amado, Zaira Ivette
  • KERVELLA, Delphine
  • Crespo, Elena
  • Meneghini, Maria
  • Torres, Irina B.
  • Martínez Gallo, Mónica
  • Len, Oscar
  • Los-Arcos, Ibai
  • Enrique, Trilla Herrera
  • Miret Alomar, Enric
  • Moreso, Francesc
  • Bestard, Oriol
Breastfeeding; Breast cancer, Lactancia materna; Cáncer de mama, Lactància materna; Càncer de mama, Background: We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants. Methods: This was an international, multicentre, hospital-based, retrospective cohort study including BRCA carriers diagnosed with stage I-III invasive breast cancer at age 40 years or younger between January 2000 and December 2020 (NCT03673306). Locoregional recurrences and/or contralateral breast cancers, disease-free survival (DFS) and overall survival (OS) were compared between patients who breastfed after delivery and those who did not. Results: Among 4732 patients included from 78 centres worldwide, 659 had a pregnancy after breast cancer diagnosis, of whom 474 delivered a child. After excluding patients with uptake of bilateral risk-reducing mastectomy prior to delivery (n = 225) or unknown breastfeeding status (n = 71), 110 (61.8%) breastfed (median duration 5 months) and 68 (38.2%) did not breastfeed. Compared to patients in the no breastfeeding group, those who breastfed were more frequently nulliparous at breast cancer diagnosis (61.8% vs 45.6%) and did not report prior smoking habit (71.8% vs 57.4%).After a median follow up of 7.0 years following delivery, 7-year cumulative incidence of locoregional recurrences and/or contralateral breast cancers was 29% in the breastfeeding group and 37% in the no breastfeeding group (adjusted subdistribution hazard ratio[HR]=1.08, 95%CI 0.57-2.06). No difference in DFS (aHR = 0.83, 95%CI 0.49-1.41) nor in OS (aHR = 1.32, 95%CI 0.31-5.66) was observed. Conclusions: Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers, emphasizing the possibility of achieving a balance between maternal and infant needs without compromising oncological safety., LD received a research fellowship grant from the “Instituto de Salud Carlos III” [FI22/00252]. OB’s research activity is partly supported by Instituto de Salud Carlos III (ISCII) (grant numbers PI19/01710 and PI22/01019) (Cofunded by European Regional Development Fund, ERDF-ESF, a way to build Europe) and RICORS (redes de Investigación Cooperativa Orientadas a Resultados en Salud) consortia by the Instituto de Salud Carlos III. In addition, the work was partially funded by a European Union’s Horizon 2020 research and innovation program under grant agreement No 754995 (EUTRAIN). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding institutions.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Immunosuppressant drugs and quality-of-life outcomes in kidney transplant recipients: An international cohort study (EU-TRAIN)

  • Girardin, François R
  • Nicolet, Anna
  • Bestard, Oriol
  • lefaucheur, carmen
  • Budde, Klemens
  • Halleck, Fabian
Immunosuppressant; Quality of life; Transplantation, Immunosupressor; Qualitat de vida; Trasplantament, Inmunosupresor; Calidad de vida; Trasplante, Introduction: Patient-Reported Outcomes (PRO) integrate a wide range of holistic dimensions that arenot captured within clinical outcomes. Particularly, from induction treatment to maintenance therapy, patient quality-of-life (QoL) of kidney transplant recipients have been sparsely investigated in international settings. Methods: In a prospective, multi-centric cohort study, including nine transplant centers in four countries, we explored the QoL during the year following transplantation using validated elicitation instruments (EQ-5D-3L index with VAS) in a population of kidney transplant patients receiving immunosuppressive therapies. Calcineurin inhibitors (tacrolimus and ciclosporin), IMPD inhibitor (mycophenolate mofetil), and mTOR inhibitors (everolimus and sirolimus) were the standard-of-care (SOC) medications, together with tapering glucocorticoid therapy. We used EQ-5D and VAS data as QoL measures alongside descriptive statistics at inclusion, per country and hospital center. We computed the proportions of patients with different immunosuppressive therapy patterns, and using bivariate and multivariate analyses, assessed the variations of EQ-5D and VAS between baseline (i.e., inclusion Month 0) and follow up visits (Month 12). Results: Among 542 kidney transplant patients included and followed from November 2018 to June 2021, 491 filled at least one QoL questionnaire at least at baseline (Month 0). The majority of patients in all countries received tacrolimus and mycophenolate mofetil, ranging from 90.0% in Switzerland and Spain to 95.8% in Germany. At M12, a significant proportion of patients switched immunosuppressive drugs, with proportion varying from 20% in Germany to 40% in Spain and Switzerland. At visit M12, patients who kept SOC therapy had higher EQ-5D (by 8 percentage points, p < 0.05) and VAS (by 4 percentage points, p < 0.1) scores than switchers. VAS scores were generally lower than EQ-5D (mean 0.68 [0.5–0.8] vs. 0.85 [0.8–1]). Discussion: Although overall a positive trend in QoL was observed, the formal analyses did not show any significant improvements in EQ-5D scores or VAS. Only when the effect of a therapy use was separated from the effect of switching, the VAS score was significantly worse for switchers during the follow up period, irrespective of the therapy type. If adjusted for patient characteristics and medical history (e.g., gender, BMI, eGRF, history of diabetes), VAS and EQ-5D delivered sound PRO measures for QoL assessments during the year following renal transplantation., The project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 754995. Open access funding by University of Lausanne.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept

  • Pernin, Vincent
  • Meneghini, Maria Antonia Emilia
  • Torija Recasens, Alba
  • Del Bello, Arnaud
  • Sanz-Muñoz, Iván
  • Crespo Gimeno, Elena Isabel
  • Bestard Matamoros, Oriol
  • Donadeu Casassas, Laura
  • Jouve, Thomas
Inhibidores de la calcineurina; Vacunación antigripal; Trasplante de riñón, Calcineurin inhibitors; Influenza vaccination; Kidney transplantation, Inhibidors de la calcineurina; Vacunació antigripal; Trasplantament de ronyó, Emerging data suggest that costimulation blockade with belatacept effectively controls humoral alloimmune responses. However, whether this effect may be deleterious for protective anti-infectious immunity remains poorly understood. We performed a mechanistic exploratory study in 23 kidney transplant recipients receiving either the calcineurin-inhibitor tacrolimus (Tac, n=14) or belatacept (n=9) evaluating different cellular immune responses after influenza vaccination such as activated T follicular Helper (Tfh), plasmablasts and H1N1 hemagglutinin (HA)-specific memory B cells (HA+mBC) by flow-cytometry, and anti-influenza antibodies by hemagglutination inhibition test (HI), at baseline and days 10, 30 and 90 post-vaccination. The proportion of CD4+CD54RA-CXCR5+ Tfh was lower in belatacept than Tac patients at baseline (1.86%[1.25-3.03] vs 4.88%[2.40-8.27], p=0.01) and remained stable post-vaccination. At M3, HA+mBc were significantly higher in Tac-treated patients (0.56%[0.32-1.49] vs 0.27%[0.13-0.44], p=0.04) and correlated with activated Tfh numbers. When stratifying patients according to baseline HA+mBc frequencies, belatacept patients with low HA+mBC displayed significantly lower HA+mBc increases after vaccination than Tac patients (1.28[0.94-2.4] vs 2.54[1.73-5.70], p=0.04). Also, belatacept patients displayed significantly lower seroprotection rates against H1N1 at baseline than Tac-treated patients (44.4% vs 84.6%) as well as lower seroconversion rates at days 10, 30 and 90 after vaccination (50% vs 0%, 63.6% vs 0%, and 63.6% vs 0%, respectively). We show the efficacy of belatacept inhibiting T-dependent antigen-specific humoral immune responses, active immunization should be highly encouraged before starting belatacept therapy., This work was supported by the Instituto de Salud Carlos III (ISCIII) (grant numbers ICI14/00242 and PI16/01321, PI19/01710) and by the European Union’s Horizon 2020 Research and innovation program (grant agreement 754995). Also, this work was partly supported by the SLT002/16/00183 grant, from the Department of Health of the Generalitat de Catalunya by the call “Accioí instrumental de programes derecerca orientats en l’àmbit de la recerca i la innovacioí en salut.” The authors thank the Research Centers of Catalonia (CERCA) Programme/Generalitat de Catalunya for institutional support. OB was awarded with an intensification grant from the “Instituto de Salud Carlos III” [INT19/00051].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Antibody Mediated Rejection and T-cell Mediated Rejection Molecular Signatures Using Next-Generation Sequencing in Kidney Transplant Biopsies

  • Cortes Garcia, Esteban
  • Giarraputo, Alessia
  • Racapé, Maud
  • Goutaudier, Valentin
  • Ursule-Dufait, Cindy
  • de la Grange, Pierre
  • Bestard, Oriol
  • Moreso, Francesc
Kidney biopsies; Kidney transplantation; Next generation sequencing, Biopsias de riñón; Trasplante de riñón; Secuenciación de nueva generación, Biòpsies de ronyó; Trasplantament de ronyó; Seqüenciació de nova generació, Recently, interest in transcriptomic assessment of kidney biopsies has been growing. This study investigates the use of NGS to identify gene expression changes and analyse the pathways involved in rejection. An Illumina bulk RNA sequencing on the polyadenylated RNA of 770 kidney biopsies was conducted. Differentially-expressed genes (DEGs) were determined for AMR and TCMR using DESeq2. Genes were segregated according to their previous descriptions in known panels (microarray or the Banff Human Organ Transplant (B-HOT) panel) to obtain NGS-specific genes. Pathway enrichment analysis was performed using the Reactome and Kyoto Encyclopaedia of Genes and Genomes (KEGG) public repositories. The differential gene expression using NGS analysis identified 6,141 and 8,478 transcripts associated with AMR and TCMR. While most of the genes identified were included in the microarray and the B-HOT panels, NGS analysis identified 603 (9.8%) and 1,186 (14%) new specific genes. Pathways analysis showed that the B-HOT panel was associated with the main immunological processes involved during AMR and TCMR. The microarrays specifically integrated metabolic functions and cell cycle progression processes. Novel NGS-specific based transcripts associated with AMR and TCMR were discovered, which might represent a novel source of targets for drug designing and repurposing., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The EU-TRAIN study was funded by the European Union’s Horizon 2020 research and innovation program under grant agreement no. 754995. The KTD-Innov study was funded by the French government, with financial support managed by the National Research Agency (ANR) under the program “Investissements d’avenir,” with the grant agreement no. ANR-17-RHUS-0010. INSERM-Action thématique incitative sur programme Avenir (ATIP-Avenir) provided financial support.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Evaluation of non-invasive biomarkers of kidney allograft rejection in a prospective multicenter unselected cohort study (EU-TRAIN)

  • Danger, Richard
  • Catar, Rusan
  • Racapé, Maud
  • Philippe, Aurélie
  • Elias, Michelle
  • Crespo, Elena
  • Goutaudier, Valentin
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Kidney transplantation; Rejection, Biomarcadors; Trasplantament renal; Rebuig, Biomarcadores; Trasplante renal; Rechazo, Non-invasive biomarkers are promising tools for improving kidney allograft rejection monitoring, but their clinical adoption requires more evidence in specifically designed studies. To address this unmet need, we designed the EU-TRAIN study, a large prospective multicentric unselected cohort funded by the European Commission. Here, we included consecutive adult patients who received a kidney allograft in nine European transplant centers between November 2018 and June 2020. We prospectively assessed gene expression levels of 19 blood messenger RNAs, four antibodies targeting non-human leukocyte antigen (HLA) endothelial antigens, together with circulating anti-HLA donor-specific antibodies (DSA). The primary outcome was allograft rejection (antibody-mediated, T cell-mediated, or mixed) in the first year post-transplantation. Overall, 412 patients were included, with 812 biopsies paired with a blood sample. CD4 gene expression was significantly associated with rejection, while circulating anti-HLA DSA had a significant association with allograft rejection and a strong association with antibody-mediated rejection. All other tested biomarkers, including AKR1C3, CD3E, CD40, CD8A, CD9, CTLA4, ENTPD1, FOXP3, GZMB, ID3, IL7R, MS4A1, MZB1, POU2AF1, POU2F1, TCL1A, TLR4, and TRIB1, as well as antibodies against angiotensin II type 1 receptor, endothelin 1 type A receptor, C3a and C5a receptors, did not show significant associations with allograft rejection. The blood messenger RNAs and non-HLA antibodies did not show an additional value beyond standard of care monitoring parameters and circulating anti-HLA DSA to predict allograft rejection in the first year post-transplantation. Thus, our results open avenues for specifically designed studies to demonstrate the clinical relevance and implementation of other candidate non-invasive biomarkers in kidney transplantation practice., The EU-TRAIN study was funded by the European Union’s Horizon 2020 research and innovation program under grant agreement no. 754995. VG received grants from the French-Speaking Society of Transplantation and the French Foundation for Medical Research. RD was supported by the EU-TRAIN study and the ANR project KTD-innov (ANR-17-RHUS-0010) thanks to the French Government financial support managed by the National Research Agency (ANR) within “Investments into the Future” program. OA received a grant from the Foundation Bettencourt-Schueller.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

High-dimensional mass cytometry identified circulating natural killer T-cell subsets associated with protection from cytomegalovirus infection in kidney transplant recipients

  • JOUVE, Thomas
  • Bin, Sofia
  • Hartzell, Susan
  • Torija Recasens, Alba
  • Jarque, Marta
  • KERVELLA, Delphine
  • Zuñiga-Vergara, Jose-Miguel
  • Font-Miñarro, Cristina
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Perelló, Manel
  • Donadeu Casassas, Laura
  • Martínez Gallo, Mónica
  • Meneghini, Maria
  • TOAPANTA, NÉSTOR
  • Moreso, Francesc
  • Bestard, Oriol
  • Crespo, Elena
Cytomegalovirus; Kidney transplantation; Mass spectrometry, Citomegalovirus; Trasplante de riñón; Espectrometría de masas, Citomegalovirus; Trasplantament de ronyó; Espectrometria de masses, Cytomegalovirus (CMV) infection is associated with poor kidney transplant outcomes. While innate and adaptive immune cells have been implicated in its prevention, an in-depth characterization of the in vivo kinetics of multiple cell subsets and their role in protecting against CMV infection has not been achieved. Here, we performed high-dimensional immune phenotyping by mass cytometry, and functional assays, on 112 serially collected samples from CMV seropositive kidney transplant recipients. Advanced unsupervised deep learning analysis was used to assess immune cell populations that significantly correlated with prevention against CMV infection and anti-viral immune function. Prior to infection, kidney transplant recipients who developed CMV infection showed significantly lower CMV-specific cell-mediated immune (CMI) frequencies than those that did not. A broad diversity of circulating cell subsets within innate and adaptive immune compartments were associated with CMV infection or protective CMV-specific CMI. While percentages of CMV (tetramer-stained)-specific T cells associated with high CMI responses and clinical protection, circulating CD3+CD8midCD56+ NK-T cells overall strongly associated with low CMI and subsequent infection. However, three NK-T cell subsets sharing the CD11b surface marker associated with CMV protection and correlated with strong anti-viral CMI frequencies in vitro. These data were validated in two external independent cohorts of kidney transplant recipients. Thus, we newly describe the kinetics of a novel NK-T cell subset that may have a protective role in post-transplantation CMV infection. Our findings pave the way to more mechanistic studies aimed at understanding the function of these cells in protection against CMV infection., LD received a research fellowship grant from the “Instituto de Salud Carlos III” (FI22/00252). TJ received a fellowship grant from the European Society of Organ Transplantation (2020 fellowship grant). PC is acting as a consultant for Chinook Therapeutics and has received research funding from Chinook Therapeutics. OB’s research activity is partly supported by Instituto de Salud Carlos III (grant numbers PI19/01710 and PI22/01019; cofunded by the European Regional Development Fund, a way to build Europe) and redes de Investigación Cooperativa Orientadas a Resultados en Salud consortia by the Instituto de Salud Carlos III. Also, the work was partially funded by a European Union Horizon 2020 research and innovation program under grant agreement 754995 (EUTRAIN).